Zurich, November 22

Welcome to hubXchange’s Europe CNS Therapeutics Xchange 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing CNS therapies.
Discussion topics will cover Preclinical, Clinical Studies and Drug Delivery.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Please note this is an In-Person meeting. 

VENUE DETAILS: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10 – 8152 Opfikon, Switzerland


  • Methods to increase the success rates of drugs entering clinical phases
  • Novel strategies for reverse translation of temporal biomarkers for CNS drug development
  • Fluid and digital biomarkers in neurodegenerative disorders
  • Utilizing clinical biomarkers to enhance drug development in neurodegenerative diseases
  • Transcytosis-mediated brain delivery for proteins, antibodies, oligonucleotides, and small molecules
  • How AI can improve drug discovery

Full Xchange Agenda

Click on each track for detailed agenda


Titles and Bullets
8:00 – 8:30



8:30 – 9:00

Opening Address & Keynote Presentation by Cambridge Cognition

Digital Technology to Address Challenges in CNS Clinical Trials

Digital technology promises to transform CNS drug development by addressing some of the challenges that make CNS clinical trials difficult and costly. Transforming this promise to results has, however, been challenging. Here, we will share our insights and learnings from applying digital technology across different phases of CNS drug development, and discuss case studies of how digital technology can be deployed to improve the efficiency and outcomes of CNS clinical trials.

9:05 – 10:05

Skirting the cliffs in CNS drug development

  • Share experiences and “best practices” in minimizing placebo response
  • What are the best methods for the early assessment blood-brain barrier penetration?
  • How should we deal with psychiatric disease heterogeneity (“DSM-5 vs. RDoC“)?

Dr Carsten Spannhuth is a senior pharmaceutical physician and strategy leader in CNS/neuroscience clinical development. He has worked successfully in senior positions over more than two decades at pharmaceutical companies such as Sanofi, Novartis, Idorsia and Lundbeck. He is a board-certified psychiatrist with extensive clinical experience in neurology, as well as experience in clinical development, business development and post-marketing lifecycle management in neurology and psychiatry in a global, innovation-oriented environment. He is also an innovative methodology facilitator, having implemented innovative study designs and endpoints, connected sensors and digital devices in clinical development; and co-founded both a pharma and a tech start-up company.

Carsten Spannhuth
10:10 – 10:40
1-2-1 Meetings / Networking Break
10:40 – 11:10
1-2-1 Meetings / Networking Break
11:10 – 11:20
Morning Refreshments
11:20 – 12:20
How to prepare a clinical phase 1 by doing the right preclinical studies?
  • What are the goals of a clinical phase 1?
  • Can we transpose the tools used in preclinical studies to phase 1 clinical trial?
  • How to optimize and increase the success of phase 1 clinical trials by doing the right preclinical studies?

Maïtena holds a MSc in Management of Biotechnology and a Master’s degree in International business in Science. She joined SynapCell as Junior Business Developer in 2021 and was recently appointed as Applications Specialist. Her background provides her with dual skills to better understand the current needs of the biopharma industry towards drug discovery for CNS disorders. Her willingness to learn and to move EEG applications forward makes Maïtena a great asset from the valorization of SynapCell’s cutting-edge research from R&D projects to the development of new solutions’ scientific launch packages.

Maïtena Aquizerate Headshot

Venceslas holds a PhD in Neuroscience and Neuropharmacology from the University of Bordeaux, France. He then undertook his post-doc at the Institute of pharmacology and toxicology at the University of Zurich. Venceslas has been working at SynapCell since 2012, first as Neuroscientist then as Head of Science. In May 2021, he was appointed Head of Product and Portfolio Management and moved to sales as Head of Scientific Sales in 2022. Venceslas therefore brings more than 10 years’ experience in drug discovery and brain disorders. As SynapCell’s Head of product and portfolio management, he is at the cutting edge of Neuroscience research through the implementation of drug discovery programs for customers or for internal R&D projects.

Venceslas DUVEAU headshot-2
12:20 – 13:20
Networking Lunch
13:25 – 13:55
1-2-1 Meetings / Networking Break
13:55 – 14:25
1-2-1 Meetings / Networking Break
15:30 – 16:30
Evening Drinks Reception


CNS Therapeutics Xchange | Europe 2023